Merck KGaA: Bio-Techne Acquisition Improves Quality, But Stock Seems Fully Valued (MKGAF)
· seekingalpha.com
Merck KGaA (MKGAF) Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
Wolf Report is a senior analyst and private portfolio manager with over 10 years of generating value ideas in European and North American markets, and the owner...